Inclusion Criteria:

- Histologically or cytologically confirmed renal cell cancer

- Metastatic disease

- More than 75% clear cell histology

- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
conventional techniques OR ≥ 10 mm by spiral CT scan

- No prior refractory disease, defined as clinical or radiologic progression, during or
within 3 months after completion of prior interleukin-2 (IL-2)

- Nominally "good" or "intermediate" risk disease, meeting ≥ 4 out of 5 of the
following criteria:

- Hemoglobin > 10 g/dL (except for patients with hereditary hemoglobinopathy)

- ECOG performance status 0-1 (required)

- Calcium normal (corrected)

- Patients with hypercalcemia due to malignancy allowed provided it has been
controlled for > 1 month

- Primary tumor treated or resected by complete nephrectomy, partial nephrectomy,
radiofrequency ablation, or other local ablation

- Lactic dehydrogenase < 1.5 times upper limit of normal (ULN)

- No history of or current brain or CNS metastasis by CT scan or MRI within the past 30
days

- Performance status - ECOG 0-1

- More than 4 months

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 75,000/mm^3

- No history of bleeding diathesis

- PTT < 1.5 times ULN

- INR < 1.5

- Bilirubin ≤ 1.5 times ULN

- AST and ALT ≤ 2.5 times ULN

- No chronic hepatitis B or C

- Creatinine ≤ 2.0 mg/dL

- No proteinuria* by dipstick urinalysis

- Urine protein ≤ 1,000 mg by 24-hour urine collection

- No symptomatic congestive heart failure

- No uncontrolled hypertension, defined as systolic blood pressure (BP) > 160 mm Hg and
diastolic BP > 90 mm Hg

- No cardiac arrhythmia

- No peripheral vascular disease ≥ grade 2

- No clinically significant peripheral artery disease

- None of the following arterial thromboembolic events within the past 6 months:

- Transient ischemic attack

- Cerebrovascular accident

- Unstable angina pectoris

- Myocardial infarction

- Not pregnant

- No nursing during and for 3 months after completion of study treatment

- Negative pregnancy test

- Fertile patients must use effective contraception before, during, and for 3 months
after completion of study treatment

- No active infection requiring parenteral antibiotics

- No known HIV positivity

- No history of allergic reaction to antibody drugs or IL-2

- No psychiatric illness or social situation that would preclude study compliance

- No non-healing wound or fracture

- No insulin-dependent diabetes

- No other uncontrolled illness

- No other malignancy requiring active treatment within the past 2 years except
nonmelanoma skin cancer

- No prior bevacizumab

- At least 6 months since prior immunotherapy containing IL-2

- At least 2 months since prior investigational antibodies

- More than 4 weeks since prior conventional cytotoxic chemotherapy (6 weeks for
nitrosoureas or mitomycin) and recovered

- No concurrent corticosteroids except replacement corticosteroids for adrenal
insufficiency OR inhaled steroids for chronic obstructive pulmonary disease, asthma,
or allergic rhinitis

- More than 3 weeks since prior radiotherapy and recovered

- No prior radiotherapy to the only site of measurable disease unless there has been
subsequent disease progression

- More than 4 weeks since prior major surgery

- At least 24 hours since prior minor surgical procedure, placement of vascular access
device, or fine needle aspiration

- At least 30 days since prior and no other concurrent investigational agents

- More than 10 days since prior anticoagulants

- Low-dose anticoagulants for maintenance of vascular access device patency
allowed

- No concurrent therapeutic warfarin, including warfarin for treatment of deep vein
thrombosis or pulmonary embolism

- No other concurrent anticancer therapy